Generic version of Suprax to be launched in the US by Dr. Reddy’s Laboratories
DSIJ Intelligence / 28 Aug 2017
A therapeutic equivalent generic version of Suprax for oral suspension, approved by the USFDA, Cefixime for oral suspension, USP 100 mg/5 ml and 200 mg/5 ml will be launched by Dr. Reddy’s Laboratories.
A therapeutic equivalent generic version of Suprax for oral suspension, approved by the USFDA, Cefixime for oral suspension, USP 100 mg/5 ml and 200 mg/5 ml will be launched by Dr. Reddy’s Laboratories. The Suprax brand and generic had US’ sales of approximately USD 50.5 million MAT for the most recent 12 months ending in June 2017, according to IMS Health. Suprax is a registered trademark of Astellas Pharma, Inc.
Meanwhile, Dr. Reddy’s Laboratories was trading at Rs 2,059.40 per share, down by Rs 28.90 or 1.38% as at 1150 hours on Monday, on the BSE. The stock hit its intraday high and low of Rs 2,089 and Rs 2,029.70, respectively and attracted a traded volume of 5,59,237 shares and traded value of Rs 11,481.69 lakhs on the NSE.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.